Long-term use of PPIs not linked to all-cause mortality or gastroenterology complications: AGA

The key findings of this study were as follows:

1. 22,125 fatalities were observed among 50,156 women and 21,731 men tracked for 832,026 person-years and a median of 13.8 years, including 4,592 deaths from cancer, 5,404 deaths from cardiovascular illnesses, and 12,129 deaths from other causes.

2. PPI users had considerably greater odds of all-cause death and mortality owing to cancer, cardiovascular disease, respiratory illness, and digestive disease compared to non-users.

3. The relationships were diminished and no longer statistically significant after adding lag times of up to six years.

4. PPI usage for a longer period of time did not increase the risk of all-cause and cause-specific death.

In conclusion, the findings of this study clearly indicate that the long-term usage of proton pump inhibitors is not associated with cases of gastroenterology complications. The working staff should consider this and hand out the PPI whenever needed.

Reference:

Lo, C.-H., Ni, P., Yan, Y., Ma, W., Joshi, A. D., Nguyen, L. H., Mehta, R. S., Lochhead, P., Song, M., Curhan, G. C., Cao, Y., & Chan, A. T. (2022). Association of Proton Pump Inhibitor Use With All-cause and Cause-specific Mortality. In Gastroenterology. Elsevier BV. https://doi.org/10.1053/j.gastro.2022.06.067